Determining the Value Contribution of Selexipag for the Treatment of Pulmonary Arterial Hypertension (PAH) in Spain Using Reflective Multi-Criteria Decision Analysis (MCDA)
Orphanet Journal of Rare Diseases - United Kingdom
doi 10.1186/s13023-018-0966-4
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2018
Authors
Publisher
Springer Science and Business Media LLC